Lipoprotein glomerulopathy N05.2; E78.)

Rare congenital glomerulopathy with deposits of abnormal lipoproteins within the glomerulum, predominantly described in the Japanese and Chinese populations. These consist of ApoE mutants (Saito T et al. 2006).

This is caused by mutations in the APOE gene (Kato T et al. 2019; Ku M et al. 2019) which is located on chromosome 19q13.32. The different mutations lead to pathogenic lipoproteins (see below apolipoprotein E variants)

Hyperlipoproteinemia type III; development of a glomerulopathy with proteinuria, possibly development of a nephrotic syndrome.

Kidney: Signs of a membranous nephropathy with electron dense depots in the subepithelial, subendothelial and mesangial areas.

Fibrates

1. Kato T et al (2019) A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes. CEN Case Rep 8:106-111.
2. Ku M et al (2019) A novel apolipoprotein E mutation (p.Arg150Cys) in a Chinese patient with lipoprotein glomerulopathy. Chin Med J 132:237239.
3. Magistroni R et al (2013) Lipoprotein Glomerulopathy Associated with a mutation in Apolipoprotein E. Clin Med Insights Case Rep 6: 189-196.
4. Saito T et al (2006) Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am. J. Kidney Dis 47: 199-211.